Vanguard Global Advisers
KYMR icon

Vanguard Global Advisers’s Kymera Therapeutics KYMR Stock Holding History

Vanguard Global Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
28,352
+1,204
+4% +$103K ﹤0.01% 970
2026
Q1 		$2.26M Buy
+27,148
New +$2.15M ﹤0.01% 1111

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Global Advisers's KYMR Position: Q2 2026 in Review

Vanguard Global Advisers increased its Kymera Therapeutics (KYMR) stake by 4.4% in Q2 2026, buying an estimated $103K and bringing the position to 28,352 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #970.

Vanguard Global Advisers first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 271 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Vanguard Global Advisers held 28,352 shares of Kymera Therapeutics worth $3.25M as of Q2 2026.
  • Vanguard Global Advisers bought 1,204 Kymera Therapeutics shares in Q2 2026, an estimated $103K.
  • Kymera Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #970 holding.
  • Vanguard Global Advisers first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 271 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.